Workflow
SCPH Alert: Monsey Firm of Wohl & Fruchter Investigating Fairness of the Sale of scPharmaceuticals to MannKind
scPharmaceuticals scPharmaceuticals (US:SCPH) GlobeNewswire News Roomยท2025-08-25 19:58

Core Viewpoint - Wohl & Fruchter LLP is investigating the fairness of the sale of scPharmaceuticals, Inc. to MannKind Corporation for $5.35 per share in cash, plus a contingent value right offering milestone-based payments of up to $1.00 per share [1][3]. Summary by Relevant Sections Sale Details - scPharmaceuticals, Inc. has agreed to be sold to MannKind Corporation for $5.35 per share in cash, along with a non-tradable contingent value right that offers milestone-based payments of up to $1.00 per share [1][3]. Price Evaluation - The sales price of $5.35 per share is below the price targets set by multiple Wall Street analysts prior to the announcement, indicating potential undervaluation [2][3]. - Analysts' price targets include $25.00 by TD Cowen, $18.00 by H.C. Wainwright, $13.00 by Jefferies, and $12.00 by Craig-Hallum [5]. Investigation Rationale - The investigation aims to determine whether the SCPH Board of Directors acted in the best interests of shareholders and if the agreed price is fair, along with the completeness of material information disclosed regarding the transaction [3].